Corcept Therapeutics Announces fourth quarter and full-year 2018 Audited Financial Results and provides corporate update

NEXT STORY
Sanofi : Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies
PREV STORY
Immunomedics Reports Results For Period Ended December 31, 2018, Strengthens Board And Announces Senior Leadership Changes
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO

- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell ...

author_avatar
NASDAQ Market News

Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS’ Lead Anti-infective Candidate SCY-078

Presentations support SCY-078's potential as a novel treatment for Candida infections including multidrug-resistant strains Favorable ...

author_avatar
NASDAQ Market News

Medtronic Initiates PRODIGY – a Global Study to Identify Those at High Risk for Opioid Induced Respiratory Depression, a Preventable Form of Respiratory Compromise

DUBLIN - May 31, 2017 - Medtronic plc (NYSE: MDT) recently launched PRODIGY, a ...

author_avatar
NASDAQ Market News